eClinical Technology and Industy News

Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma

Excerpt from the Press Release:

SAN DIEGO, March 30, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy of the combination in subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy.

“This Phase 3 trial follows our open label Phase 2 study which showed impressive clinical results for the combination of Opdivo and HBI-8000 to treat melanoma,” said Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO. “HBI-8000 has been shown to enhance the efficacy of Opdivo through one of its mechanisms of action that controls acetylation and nuclear transportation of PD-L1.”

HUYABIO will be the sponsor of the trial. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study. Opdivo® is a registered trademark of Bristol Myers Squibb.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives